WearLinq
Wireless, clinical-grade 6-lead ECG wearable and IDTF reporting service for remote cardiac monitoring.
Website: https://wearlinq.com
Cover Block
PUBLIC
| Attribute | Details |
|---|---|
| Name | WearLinq |
| Tagline | Wireless, clinical-grade 6-lead ECG wearable and IDTF reporting service for remote cardiac monitoring. |
| Headquarters | 119 University Ave, Palo Alto, California, 94301, United States [ZoomInfo.com, 2026] |
| Founded | 2019 |
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Series A (total disclosed ~$26,300,000) |
Links
PUBLIC
- Website: https://wearlinq.com
- LinkedIn: https://www.linkedin.com/company/wearlinq
- App Store: https://apps.apple.com/app/wearlinq/id6739941626
Executive Summary
PUBLIC WearLinq is a Palo Alto-based digital health company that has developed a wireless, FDA-cleared 6-lead ECG wearable and an integrated diagnostic service, a combination that addresses a persistent gap in remote cardiac monitoring between consumer-grade wearables and cumbersome clinical equipment [LinkedIn]. Founded in 2019 by Konrad Morzkowski and Yuxin Liu, the company has moved from concept to a commercialized product, the eWave device, which it positions as the first of its kind to offer multidimensional heart views from a single patch [LinkedIn, mtec-sc.org]. The founding team's background in bioengineering from Stanford University provides a relevant technical foundation, though their public record does not yet detail prior commercial or sales leadership experience in the medical device sector [bioengineering.stanford.edu, 2026].
Financially, the company has secured significant backing, closing a $14 million Series A equity round led by AIX Ventures in December 2025 alongside $5 million in venture debt, bringing its total disclosed funding to approximately $26.3 million from a syndicate of fifteen investors [HLTH, Dec 2025] [Tracxn]. Its business model is distinctly B2B, combining hardware sales with software and reporting services through its owned Independent Diagnostic Testing Facility (IDTF), aiming for reimbursement pathways rather than direct-to-consumer wellness sales [LinkedIn]. Over the next 12-18 months, the key metrics to watch will be the commercial rollout velocity of the eWave device, the expansion of its AI-augmented analysis pipeline beyond cardiac monitoring as hinted by management, and the traction of its integrated service model with cardiology practices and health systems [massdevice.com, 2026].
Data Accuracy: GREEN -- Core product claims and recent funding round confirmed by multiple independent sources including HLTH, LinkedIn, and company website.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Series A (total disclosed ~$26,300,000) |
Company Overview
PUBLIC
WearLinq was founded in 2019 by Konrad Morzkowski and Yuxin Liu [PrivCo]. The company is headquartered in Palo Alto, California, at 119 University Ave [ZoomInfo.com, 2026]. Its founding premise was to build a clinical-grade cardiac monitoring system that combined a proprietary wearable device with a full diagnostic service, moving beyond the limitations of consumer fitness trackers and traditional Holter monitors.
The company's key operational milestone was the acquisition of AMI Cardiac Monitoring, an Independent Diagnostic Testing Facility (IDTF), in May 2024 [Crunchbase, May 2024]. This move established WearLinq's clinical operations in Rockville, Maryland, and gave it the regulatory foundation to bill for diagnostic services. The core product, the eWave wearable ECG monitor, received FDA clearance, which the company describes as the first for a wireless, six-lead cardiac monitor [LinkedIn].
A significant funding milestone was reached in December 2025 with the close of a $14 million Series A equity round led by AIX Ventures, which was announced alongside a separate $5 million venture debt facility [HLTH, Dec 2025]. This capital is earmarked for scaling commercial operations.
Data Accuracy: GREEN -- Company details and founding year confirmed by multiple databases; acquisition and recent funding round corroborated by press releases and investor announcements.
Product and Technology
MIXED WearLinq’s product is a vertically integrated diagnostic service, anchored by its FDA-cleared hardware. The company’s eWave device is a wireless, stretchable sensor that captures a six-lead electrocardiogram (ECG), a specification it promotes as the first of its kind to receive FDA clearance for cardiac monitoring [LinkedIn]. This form factor, described as the world’s smallest and lightest stretchable ECG wearable, is designed for five days of continuous use on a single charge and pairs directly with a patient’s smartphone [sg.linkedin.com, 2026] [wearlinq.com, 2026]. The clinical-grade data is transmitted in near-real-time to a cloud platform where AI-augmented analysis flags arrhythmias like atrial fibrillation [startup-seeker.com].
The service layer is what distinguishes WearLinq from a pure hardware vendor. The company operates as an Independent Diagnostic Testing Facility (IDTF), providing expedited cardiology reports to ordering clinicians, often in under 48 hours [finsmes.com, 2025]. This end-to-end model,device, data transmission, AI analysis, and certified reporting,is marketed as a tool for reducing care costs through earlier detection and by minimizing the need for repeat testing [LinkedIn]. The patient-facing mobile app allows for 24/7 continuous recording and includes automated alerts for low battery or poor signal quality [apps.apple.com, 2026] [cardiovascularbusiness.com, 2026].
Public statements indicate an expanding pipeline of AI products and a vision to move beyond cardiac monitoring, though specific features or timelines are not detailed [massdevice.com, 2026]. The technology stack is inferred from job postings to include cloud infrastructure for data handling and machine learning operations, though the specific providers beyond a noted partnership with AWS are not confirmed [AWS Startups].
Data Accuracy: GREEN -- Product claims are consistent across the company website, press releases, and third-party coverage. FDA clearance and IDTF status are referenced in multiple sources.
Market Research
PUBLIC The market for remote cardiac monitoring is expanding beyond traditional Holter devices, driven by a convergence of clinical need, reimbursement evolution, and a push for more patient-friendly diagnostic tools.
Quantifying the total addressable market for clinical-grade, multi-lead wearable ECG monitors is challenging, as most public reports aggregate broader remote patient monitoring or cardiac diagnostics categories. One frequently cited analysis from Grand View Research valued the global remote patient monitoring market at $4.5 billion in 2023, projecting a compound annual growth rate of 18.5% through 2030 [Grand View Research, 2024]. Within that, the cardiac monitoring segment represents a substantial portion. A more specific report from MarketsandMarkets estimated the global ECG market, including devices and services, at $7.7 billion in 2024, growing to $10.6 billion by 2029 [MarketsandMarkets, 2024]. These figures serve as analogous market proxies, as WearLinq's specific niche of FDA-cleared, 6-lead wearable patches with integrated diagnostic services is not yet broken out in major syndicated reports.
Demand is anchored in a significant and growing patient population. The prevalence of cardiac arrhythmias like atrial fibrillation (AFib) is increasing with an aging global demographic, and earlier detection is a clinical priority to prevent stroke and heart failure. This clinical imperative is supported by evolving reimbursement pathways in the United States. The expansion of CPT codes for remote physiologic monitoring and the establishment of Medicare reimbursement for wearable cardiac monitors worn for extended periods (e.g., 14-30 days) create a clearer economic model for healthcare providers to adopt these technologies [American College of Cardiology, 2023]. Furthermore, the shift towards value-based care and hospital-at-home programs incentivizes health systems to invest in tools that can reduce costly emergency department visits and hospital readmissions through proactive, data-driven management.
Key adjacent markets include consumer wellness wearables (e.g., Apple Watch, Fitbit) and traditional Holter monitor services. While consumer devices have raised awareness of heart rhythm tracking, they primarily offer single-lead ECG for spot checks and are not cleared for diagnostic purposes, creating a gap for clinical-grade, continuous monitoring. The traditional Holter market, valued at approximately $1.1 billion globally, is characterized by bulky, wired devices that are often cumbersome for patients and provide delayed, batch-processed data [Kalorama Information, 2023]. WearLinq's proposed market wedge sits at the intersection of these segments, aiming to displace a portion of the legacy Holter service market with a more patient-compliant, real-time enabled solution while meeting the clinical rigor that consumer devices lack.
Regulatory forces are a double-edged sword. FDA clearance is a mandatory and significant barrier to entry that validates a device for diagnostic use, but the process is lengthy and capital-intensive. The regulatory landscape also governs data privacy (HIPAA in the U.S.) and the standards for Independent Diagnostic Testing Facilities (IDTFs), which WearLinq operates. Macro forces include persistent pressure on healthcare costs, which favors technologies promising to lower the total cost of care through earlier intervention, and the accelerated adoption of telehealth infrastructure post-pandemic, which has normalized remote clinician-patient interactions.
Global Remote Patient Monitoring Market (2023) | 4.5 | $B
Global ECG Market (2024) | 7.7 | $B
Traditional Holter Monitor Market | 1.1 | $B
The available sizing data suggests WearLinq is targeting a substantial and growing segment within the broader cardiac monitoring landscape. The company's success will depend on capturing share from the established Holter service market rather than expanding the total market de novo.
Data Accuracy: YELLOW -- Market sizing figures are drawn from third-party analyst reports for analogous sectors; specific TAM for 6-lead wearable ECG patches is not publicly broken out.
Competitive Landscape
MIXED
WearLinq's market position is defined by its attempt to occupy a middle ground between consumer-grade wearables and cumbersome clinical hardware, a wedge that attracts both direct competitors and substitutes from adjacent categories.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| WearLinq | Integrated B2B service: FDA-cleared 6-lead wireless patch + IDTF reporting + AI analysis. | Series A; ~$26.3M total raised. | Combines a 6-lead, wireless form factor with a full diagnostic service (IDTF) for clinical reimbursement. | [LinkedIn]; [HLTH, Dec 2025] |
| CardioDiagnostics | Provider of AI-powered cardiovascular diagnostic tests, including epigenetic-coronary heart disease tests. | Private; funding not publicly detailed. | Focuses on epigenetic blood tests for heart disease risk, not continuous monitoring hardware. | [CB Insights, 2026] |
| Peerbridge Health | Developer of a wearable ECG patch for remote patient monitoring, emphasizing atrial fibrillation detection. | Private; funding not publicly detailed. | Offers a 2-lead adhesive patch, positioned for remote patient monitoring programs. | [CB Insights, 2026] |
The competitive map splits into three distinct segments. First, the incumbent Holter monitor and event recorder market, dominated by legacy medical device companies like Philips and iRhythm. These players offer reimbursed, multi-day monitoring but rely on bulkier hardware and slower, often manual, reporting cycles. Second, the consumer wearable segment, including Apple Watch and Fitbit, provides continuous heart rhythm data directly to users but lacks the multi-lead clinical validation and structured reporting required for formal diagnosis. Third, a growing set of remote patient monitoring (RPM) and telehealth platforms that bundle software with various FDA-cleared devices, acting as channel partners or potential substitutes.
WearLinq's defensible edge today rests on two integrated components: its 6-lead FDA clearance and its owned Independent Diagnostic Testing Facility (IDTF). The 6-lead patch provides richer diagnostic data than consumer wearables, while the IDTF status allows the company to bill Medicare and other payers directly for the diagnostic service, not just the device sale. This regulatory and reimbursement moat is durable but perishable; it depends on maintaining compliance and could be eroded if competitors achieve similar clearances and build equivalent service operations. The recent $14 million Series A led by AIX Ventures provides capital to scale this clinical-commercial integration ahead of pure-play hardware or software rivals.
The company's most significant exposure is in distribution and sales channel control. While WearLinq sells a full-stack service, it must still convince cardiology practices and health systems to adopt its specific device and reporting workflow. This pits it against larger RPM platform companies that offer a suite of devices from multiple manufacturers and may prioritize their own software ecosystem over a single hardware vendor. Furthermore, the 'eWave' device's 5-day battery life, while a noted improvement, still requires more frequent patient intervention than some longer-term implantable or wearable monitors, a potential friction point in adherence.
The most plausible 18-month scenario is one of segmentation. A 'winner' in the clinical arrhythmia monitoring niche could be WearLinq if it successfully leverages its Series A capital to build a dense network of cardiology clinic partnerships, demonstrating superior diagnostic yield and faster report turnaround that directly improves clinic revenue and patient outcomes. A 'loser' could be generic 1-2 lead patch manufacturers if payers and providers begin to demand the richer, multi-lead data that WearLinq's device provides as a standard for reimbursement, rendering simpler devices inadequate for comprehensive diagnostic studies.
Data Accuracy: YELLOW -- Competitor profiles are confirmed by a single industry database; differentiation claims are based on public company positioning.
Opportunity
PUBLIC The prize for WearLinq is a fundamental shift in the economics of cardiac diagnostics, moving from episodic, clinic-bound testing to continuous, data-driven care management.
The headline opportunity is to become the default platform for continuous, clinical-grade cardiac monitoring, displacing the legacy Holter monitor and event recorder market. This outcome is reachable because the company has already cleared the primary regulatory and technical hurdles. Its eWave device is FDA-cleared for 6-lead monitoring, a clinical-grade designation that separates it from consumer wellness trackers [LinkedIn]. The integrated Independent Diagnostic Testing Facility (IDTF) model provides a direct, reimbursable service channel into cardiology practices and health systems, a wedge that pure hardware vendors lack [LinkedIn, MTEC]. The cited evidence of a recent $14 million Series A round led by AIX Ventures, with participation from over a dozen specialized healthcare and deep-tech funds, signals institutional confidence in this commercial path [HLTH, Dec 2025].
Multiple, concrete paths exist for WearLinq to scale from its current clinical wedge to a platform of significant size.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Standard of Care for Post-Discharge Monitoring | WearLinq becomes the mandated remote monitoring tool for patients discharged after cardiac events or procedures, capturing a high-volume, recurring revenue stream. | A major health system or payer signs a multi-year, enterprise-wide contract for its cardiac care pathways. | The company's model of real-time data transmission and <48-hour reporting directly addresses hospital readmission reduction goals [finsmes.com, 2025]. Competitors like CardioDiagnostics are also targeting this hospital integration space [cbinsights.com, 2026]. |
| AI-Powered Chronic Disease Management | The platform expands beyond arrhythmia detection into predictive analytics for heart failure, hypertension, and other cardiometabolic conditions, increasing patient lifetime value. | Successful validation and publication of its AI algorithms for predicting adverse cardiac events. | The company has publicly stated an "exciting pipeline of AI products" and plans to expand its reach beyond cardiac monitoring [massdevice.com, 2026]. |
| Embedded OEM for Large Device Makers | WearLinq's stretchable sensor technology is licensed or white-labeled by a major medical device company, providing high-margin component revenue. | A strategic partnership or development agreement with an incumbent player seeking next-generation wearable form factors. | The eWave is marketed as the "world's smallest, lightest and first stretchable ECG wearable" [sg.linkedin.com/in/alexis-goh, 2026], a potentially attractive IP asset for larger firms. |
What compounding looks like is a data and distribution flywheel. Each new clinical deployment generates proprietary, longitudinal ECG data, which improves the accuracy and scope of its AI detection algorithms. Better algorithms lead to more compelling clinical outcomes data, which strengthens sales arguments to larger health systems and improves reimbursement negotiations. This commercial traction, in turn, funds further R&D into new sensor modalities and AI applications, as indicated by the company's stated expansion plans [massdevice.com, 2026]. The 2024 acquisition of AMI Cardiac Monitoring provided an initial base of clinical operations and billing expertise, jump-starting this cycle [Crunchbase].
The size of the win can be framed by a credible comparable. iRhythm Technologies, a public company in the cardiac monitoring space, achieved a market capitalization of approximately $3 billion at its peak, built on a similar model of providing monitoring devices and diagnostic services [public filings]. While iRhythm utilizes a different form factor (a single-use patch), it demonstrates the valuation potential of a scaled, data-driven cardiac diagnostics service. If WearLinq's "Standard of Care" scenario plays out, capturing a material portion of the multi-billion dollar ambulatory cardiac monitoring market, a similar platform valuation is conceivable (scenario, not a forecast).
Data Accuracy: YELLOW -- The core product claims and funding round are well-sourced from company and news outlets. Growth scenarios and the size of the win are extrapolations based on these claims and comparable market dynamics.
Sources
PUBLIC
[ZoomInfo.com, 2026] Wearlinq Funding: How Much Did They Raise & Key Investors | https://www.zoominfo.com/financial/wearlinq-inc/1263182884
[LinkedIn] Wearlinq | https://www.linkedin.com/company/wearlinq
[mtec-sc.org] Wearlinq Inc | https://mtec-sc.org/life-sciences/wearlinq-inc
[bioengineering.stanford.edu, 2026] Yuxin Liu | https://bioengineering.stanford.edu/people/yuxin-liu
[HLTH, Dec 2025] WearLinq Raises $14M to Scale Its Wireless, Clinical-Grade Heart Monitor | https://hlth.com/insights/news/wearlinq-raises-14m-to-scale-its-wireless-clinical-grade-heart-monito-2025-12-18
[Tracxn] Wearlinq - 2026 Company Profile, Team, Funding & Competitors | https://tracxn.com/d/companies/wearlinq/__xF0-KEJvH89i_M3aHlS_s_Nu2x_n1_m6RbKkTuDowG8
[massdevice.com, 2026] WearLinq to expand access to FDA-cleared wearable ECG | https://www.massdevice.com/wearlinq-expand-access-wearable-ecg/
[PrivCo] Wearlinq | https://www.privco.com/company/wearlinq
[Crunchbase, May 2024] WearLinq acquires AMI Cardiac Monitoring | https://www.crunchbase.com/acquisition/wearlinq-acquires-ami-cardiac-monitoring--395d7004
[sg.linkedin.com, 2026] Alexis Goh Weiying - Open Government Products | https://sg.linkedin.com/in/alexis-goh
[wearlinq.com, 2026] WearLinq eWave | https://wearlinq.com
[startup-seeker.com] Wearlinq | https://startup-seeker.com/company/wearlinq~com
[finsmes.com, 2025] WearLinq Secures $14M in Series A Funding | https://www.finsmes.com/2025/12/wearlinq-secures-14m-in-series-a-funding.html
[apps.apple.com, 2026] WearLinq App | https://apps.apple.com/app/wearlinq/id6739941626
[cardiovascularbusiness.com, 2026] WearLinq eWave | https://www.cardiovascularbusiness.com/topics/clinical/electrophysiology-arrhythmia/wearlinq-ewave-wearable-ecg-monitor
[AWS Startups] WearLinq | AWS Startups | https://aws.amazon.com/startups/showcase/startup-details/7754f1c5-0b2c-40e4-a95e-636c2fbcf28e
[Grand View Research, 2024] Remote Patient Monitoring Market Size Report, 2024-2030 | https://www.grandviewresearch.com/industry-analysis/remote-patient-monitoring-market
[MarketsandMarkets, 2024] ECG Market by Product, Lead Type, End User - Global Forecast to 2029 | https://www.marketsandmarkets.com/Market-Reports/electrocardiograph-ecg-market-17362324.html
[American College of Cardiology, 2023] Remote Patient Monitoring in Cardiovascular Care | https://www.acc.org/Latest-in-Cardiology/Articles/2023/07/17/14/42/Remote-Patient-Monitoring-in-Cardiovascular-Care
[Kalorama Information, 2023] Holter Monitor Systems Market | https://kaloramainformation.com/product/holter-monitor-systems-market/
[CB Insights, 2026] CardioDiagnostics | https://www.cbinsights.com/company/cardiodiagnostics
[CB Insights, 2026] Peerbridge Health | https://www.cbinsights.com/company/peerbridge-health
Articles about WearLinq
- WearLinq's 6-Lead ECG Patch Clears the FDA for Clinical Use — The Palo Alto startup's wireless wearable and IDTF service aim to replace bulky Holter monitors for arrhythmia detection, backed by $26.3 million.